Ascendis Pharma A/S (NASDAQ:ASND) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of Ascendis Pharma A/S (NASDAQ:ASND) have received an average recommendation of “Moderate Buy” from the nine ratings firms that are covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. The average 12-month target price among brokers that have covered the stock in the last year is $179.44.

A number of research analysts recently commented on ASND shares. Cantor Fitzgerald reissued an “overweight” rating and issued a $173.00 target price on shares of Ascendis Pharma A/S in a research note on Wednesday, May 15th. Morgan Stanley raised their price objective on Ascendis Pharma A/S from $116.00 to $140.00 and gave the company an “equal weight” rating in a research note on Thursday, May 16th. Wells Fargo & Company raised their price objective on Ascendis Pharma A/S from $260.00 to $262.00 and gave the company an “overweight” rating in a research note on Friday, May 3rd. Stifel Nicolaus started coverage on Ascendis Pharma A/S in a research note on Friday, May 31st. They set a “buy” rating and a $200.00 price objective on the stock. Finally, JPMorgan Chase & Co. raised their price objective on Ascendis Pharma A/S from $167.00 to $170.00 and gave the company an “overweight” rating in a research note on Friday, May 3rd.

Institutional Investors Weigh In On Ascendis Pharma A/S

Several hedge funds and other institutional investors have recently modified their holdings of ASND. Farallon Capital Management LLC purchased a new stake in Ascendis Pharma A/S in the 1st quarter worth about $16,478,000. Price T Rowe Associates Inc. MD raised its holdings in shares of Ascendis Pharma A/S by 23.3% during the first quarter. Price T Rowe Associates Inc. MD now owns 1,781,926 shares of the biotechnology company’s stock worth $269,374,000 after purchasing an additional 336,976 shares during the last quarter. Avoro Capital Advisors LLC increased its holdings in Ascendis Pharma A/S by 5.6% in the first quarter. Avoro Capital Advisors LLC now owns 3,966,666 shares of the biotechnology company’s stock valued at $599,641,000 after buying an additional 211,111 shares in the last quarter. Capital International Investors lifted its holdings in shares of Ascendis Pharma A/S by 0.5% in the 1st quarter. Capital International Investors now owns 2,191,312 shares of the biotechnology company’s stock worth $331,261,000 after acquiring an additional 10,044 shares during the last quarter. Finally, Nan Fung Group Holdings Ltd purchased a new stake in Ascendis Pharma A/S during the 1st quarter worth approximately $2,056,000.

Ascendis Pharma A/S Price Performance

NASDAQ:ASND opened at $127.85 on Friday. The company has a market cap of $7.44 billion, a P/E ratio of -13.30 and a beta of 0.59. The stock’s fifty day moving average price is $133.17 and its two-hundred day moving average price is $136.86. Ascendis Pharma A/S has a 1 year low of $85.08 and a 1 year high of $161.00.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its quarterly earnings data on Thursday, May 2nd. The biotechnology company reported ($2.48) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.57) by ($0.91). The business had revenue of $103.11 million during the quarter, compared to analysts’ expectations of $85.72 million. Ascendis Pharma A/S had a negative return on equity of 16,574.15% and a negative net margin of 152.68%. On average, analysts expect that Ascendis Pharma A/S will post -5.13 earnings per share for the current fiscal year.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.